CN102847521B - Macro-porous adsorption resin and its application - Google Patents
Macro-porous adsorption resin and its application Download PDFInfo
- Publication number
- CN102847521B CN102847521B CN 201110195335 CN201110195335A CN102847521B CN 102847521 B CN102847521 B CN 102847521B CN 201110195335 CN201110195335 CN 201110195335 CN 201110195335 A CN201110195335 A CN 201110195335A CN 102847521 B CN102847521 B CN 102847521B
- Authority
- CN
- China
- Prior art keywords
- resin
- blood
- present
- absorption
- medical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011347 resin Substances 0.000 title claims abstract description 69
- 229920005989 resin Polymers 0.000 title claims abstract description 69
- 238000001179 sorption measurement Methods 0.000 title abstract description 9
- 239000011148 porous material Substances 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000003463 adsorbent Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 239000011248 coating agent Substances 0.000 claims abstract description 4
- 238000000576 coating method Methods 0.000 claims abstract description 4
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000008280 blood Substances 0.000 claims description 41
- 210000004369 blood Anatomy 0.000 claims description 40
- 238000010521 absorption reaction Methods 0.000 claims description 23
- 239000002250 absorbent Substances 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 11
- 230000008081 blood perfusion Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 231100000614 poison Toxicity 0.000 claims description 3
- 230000007096 poisonous effect Effects 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 21
- 238000011282 treatment Methods 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 210000001124 body fluid Anatomy 0.000 description 11
- 239000010839 body fluid Substances 0.000 description 11
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 231100000167 toxic agent Toxicity 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 206010020850 Hyperthyroidism Diseases 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 108010029697 CD40 Ligand Proteins 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 150000002605 large molecules Chemical class 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 4
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 238000005411 Van der Waals force Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HLTUZPFCDXKNKS-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene ethene Chemical class C(=C)C1=C(C=CC=C1)C=C.C=C HLTUZPFCDXKNKS-UHFFFAOYSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Laminated Bodies (AREA)
Abstract
The invention relates to a medical macro-porous adsorption resin which takes styrene-divinylbenzen material resin balls as an adsorbent resin frame, the resin balls densely cover micro-pores, the pore widths of the resin balls are in a range of 22-100nm, the specific surface area of the resin balls is greater than 1000m<2>/g, and the pore volume of the resin balls is greater than 6.000e-01cc/g. The resin surface can be coated with a protein membrane as needed, and the resin surface or its coating can be processed to have a polarity as needed.
Description
Invent described technical field
The invention belongs to medical macromolecular materials and application thereof.
The prior art background
This ethene-divinylbenzene resin has been widely used in medical sorbent material, but up to the present people still do not have good explanation to this adsorbent to the absorption principle of material in the peripheral blood; Therefore its range of application is very narrow, be confined to mostly in the late stage of uremia patient treatment as the auxiliary curing mode of dialysis treatment.For in the application in other illness field then seldom, even do not make inquiries.
The disease of AIDS, cerebral infarction and classes such as hypertension, hyperthyroidism for example in depositing the difficult sufferer of generation at present adopts operation of the prior art and drug treatment all to be difficult to remarkable and lasting curative effect.Blood purification comes out for many years as the third illness therapeutic modality, does not pioneer and keep forging ahead in the difficult illness treatment field to these harm humans health but be based on previous reasons.
The content of invention
The present invention be resin balls with styrene-divinylbenzene material as the resin framework, its aperture (Pore Sizc) scope is between the 22-100 nanometer; Specific area (Snrface Area) is greater than 1000 square metres/g, between 1000 square metres/g to 3000 square metre/g; Pore volume (Pore volume) is greater than 6.000e-01cc/g, between 6.000e-01cc/g to 9.000e-01cc/g.
Macroporous absorbent resin of the present invention can take pureization processing to reach medical grade, adsorbent as blood perfusion device, absorption surpasses 10,000 except all kinds of in the blood side by side in people's extracorporal circulatory system bloody path, until surpass the exogenous and endogenous poisonous substance of the big molecule of 2,000,000 d, virus protein molecule, complex virus material, and excessive molecular weight surpass 10,000 d, until surpassing the macromolecular components that 2,000,000 d, diameter surpass 100 nanometers; Blood samples of patients is purified, reach and alleviate and even cure all kinds of illness that cause because of septicemia.
A kind of concrete scheme of resin of the present invention can be: aperture (Pore width) scope is in the 22-25 nanometer; Specific area (Snrface Area Date) is greater than 1100 square metres/g; Pore volume (Pore volume) is greater than 6.500e-01cc/g.
The another kind of concrete scheme of resin of the present invention can be: its aperture (Pore width) scope is in the 30-35 nanometer; Specific area (Snrface Area Date) is greater than 1900 square metres/g; Pore volume (Pore volume) is greater than 6.000e-01cc/g.
Another concrete scheme of resin of the present invention can be: its aperture (Pore width) scope 92-100 nanometer; Specific area (Snrface Area Date) is greater than 1000 square metres/g; Pore volume (Pore volume) is greater than 7.000e-01cc/g.
The above-mentioned performance indications data of resin of the present invention are taken under the dry state state, and when doing the polymeric adsorbent use, resin is in hygrometric state.According to calculating, the aperture of resin can enlarge about 2 to 6 times than dry state during hygrometric state.That is, the maximum diameter of hole can reach about 600 nanometers.
Macroporous absorbent resin of the present invention surface can coat protein film as required.
Macroporous absorbent resin of the present invention surface or its coating can also be done the polarity processing as required makes it have polarity.
Embodiments of the invention
One of embodiment:
Resin of the present invention uses as the adsorbent of blood perfusion device, and blood perfusion device is placed in AIDS patient's the extracorporeal circulation blood circuit, and absorption is also got rid of AIDS virus, complex immunity virus and inflammatory factor in the blood samples of patients, to such an extent as to alleviate treatment of AIDS.
Two of embodiment:
Resin of the present invention uses as the adsorbent of blood perfusion device, and blood perfusion device is placed in cerebral infarction patient's the extracorporeal circulation blood circuit, and absorption is also got rid of B2-microglobulin and inflammatory factor in the blood samples of patients, cures the cerebral infarction illness to such an extent as to alleviate.
Three of embodiment:
Resin of the present invention uses as the adsorbent of blood perfusion device, and blood perfusion device is placed in the extracorporeal circulation blood circuit of patients with hypertension, and absorption is also got rid of the parathormone high pressure factor and inflammatory factor in the blood samples of patients, cures the hypertension illness to such an extent as to alleviate.
Four of embodiment:
Resin of the present invention uses as the adsorbent of blood perfusion device, blood perfusion device is placed in hyperthyroid's the extracorporeal circulation blood circuit, absorption is also got rid of the excessive thyroxine factor and inflammatory factor in the blood samples of patients, cures the hyperthyroidism illness to such an extent as to alleviate.
In conjunction with the embodiments the present invention is described in detail:
The material absorption principle of macroporous absorbent resin of the present invention is physical absorption, and active force mainly is the Van der Waals force that material surface exists.At surpassing the big molecule of 10,000 d or greater than the super large Molecular Adsorption active force of the 2000000 d Van der Waals force that also to be material surface produce when the contact.The key that can adsorb big molecule and super large molecule is that resin of the present invention has the aperture of super large, pore volume and specific area.When the big molecule that is adsorbed touches resin of the present invention, model ylid bloom action power can be drawn into these big molecules and the super large molecule aperture by super large in the resin balls, and the pore volume of resin balls super large and specific area can retain and be included on the resin balls surfaces externally and internally separating its peripheral blood that passes through from resin balls or the body fluid; When treatment finishes, extract blood perfusion device and will be attracted to external that super large molecular substance on the resin abandons at leisure, reach the purpose that purifies the blood and treat illness.
Because most super large molecular toxicity materials belong to toxic protein, the present invention coats protein film at resin surface, makes it have compatibility to the protein type poisonous substance, can strengthen the suction-operated to toxicant.
And most of toxicants surface all has strong or weak polarity, comprises negative electrode or anode; The perhaps regular or irregular reverse with environmental factor.At the polarity that the adsorbed material surface has, can be correspondingly with resin surface polarity of the present invention processing.Big molecule or super large molecule that the surface has polarity contact with resin surface under fluid pressure, little active force of homopolar-repulsion can squeeze brokenly the polarity film that may be coated on big molecule or super large molecular surface, it is deflected at the volley, cause its surface polarity and change; Heteropole is inhaled mutually and can be strengthened resin to the absorption affinity of big molecule or super large molecule.
Body fluid under the health status in the human body is a kind of equilibrium state; Illness state servant's body fluid is uneven attitude, presents acid attitude on the whole more.Resin of the present invention is influenced by the poised state of body fluid to the suction-operated of material in the body fluid, then have the situation of so-called " competitive Adsorption " for adsorbed material, and the material of overbalance state preferentially is adsorbed, the attitude so that body fluid tends to balance.Therefore the material overwhelming majority of being peeled off absorption by resin of the present invention from peripheral blood or body fluid is the toxicant that influences blood and/or isohydria, or influence the excessive composition of blood and/or isohydria, thereby make blood or the body fluid state that restores balance; In this separation adsorption process, can be carried secretly absorption to human body beneficial's material, but its amount of being carried secretly absorption is not understood manyly under the state of " competitive Adsorption " yet, and the recovery capability of human body self can make these losses be compensated very soon.
The inventor executes the mechanism of controlling at the illness that relates among the embodiment and is described as follows based on the study to modern cell, molecule and gene medical knowledge:
AIDS is century property illness, still can't give treatment at present.Analyze its reason and be because AIDS virus HIV and with CD4 molecule and the HHV series complex virus of HIV virus coexistence, all in 100,000 d level scopes, diameter about about 200 nanometers, belongs to the super large molecule to their itself molecular weight mostly.And this HIV virus at body fluid, comprise that the mode that exists in the peripheral blood is to be coated by the huge CD4 that has a liking in cell or the immune system T cell earlier, HIV attacks and captures the huge CD4 that has a liking in cell or the immune system T cell, makes the immune system forfeiture to the recognition function of HIV virus; Then HIV enters a large amount of breedings in the immune T-CD4 lymphocyte, and the DNA gene strand in the while attack cells, disintegrates the human immune system up to making its collapse, and various opportunistic diseases will be invaded human body without barrier and be caused death.Medicine can't penetrate the infected huge adventitia of having a liking for cell and/or T-CD4 in the immune system that coats HIV virus, thereby up to the present, does not have medicine substantial kill activity directly or indirectly to take place to HIV.Comprise the HIV that exists in the blood at body fluid, take the way that exchanges blood transfusion also of no avail.Because can't the instantaneously changing whole blood, even the instantaneously changing whole blood also can't all be removed infected T-CD4 from immune system; And the stimulation of change-blood back new blood can make HIV and the infected T-CD4 ground fast breeding that is further intensified, and consequence is the process of having accelerated the healthy body of virus infraction.
Adopt resin of the present invention to body fluid, comprise that the suction-operated of HIV in the blood and various compound toxicants is based on the Van der Waals force of material surface; And whether coated irrelevant by the infected huge CD4 molecule of having a liking for cell or immune t-cell with HIV or other toxicant surfaces.Separate absorption HIV and infectedly hugely have a liking for cell or T-CD4 and compound toxicant, and with blood purification, relevant with aperture, pore volume and the specific area of resin.The ultra-large aperture that resin of the present invention has, pore volume and specific area, can separate absorption HIV, comprise viral complex virus and infected huge have a liking for cell or the T-CD4 of HHV system, and can and remain in the resin nearly all big molecule and the absorption of super large molecular toxicity material, simultaneously with blood purification.
Resin of the present invention shows that in the Various types of data such as aperture, pore volume and specific area of carrying out measuring when species analysis detects this resin can adsorb and contain the super large molecular substance of millions of grades of d fully, for example: blue Buddhist nun's alkali.So absorption only have relative molecular weight the HIV virus of hundreds thousand of d level scopes, infected huge have a liking for cell, T-CD4 molecule, HHV be complex virus and comprise B2-microglobulin, TNF, parathormone inflammatory mediator, interleukin-11,1B, 6, etc. inflammatory factor all be out of question.
Resin surface of the present invention can coat protein film to increase the affinity to virus protein, is conducive to its absorption.The polarity processing can also be done in the surface of this resin surface or coating film, also can increase the physical absorption function that his-and-hers watches are worn viruses molecule or the toxicant of polarity.
The inventor obtained blood sample in a specific aim clinical testing, to its detection: the AIDS check is positive before the art; Through adopting resin of the present invention to carry out blood purification, postoperative AIDS detects to become and transfers feminine gender to.Owing to lack the comprehensive detection means of the material that is adsorbed, this detection is so that CD4 and the detection of related substances HIV infection index are as the criterion.And the inflammatory factors such as B2-microglobulin, interleukin-11 B, interleukin 6, TNF in addition that can detect in the material that is adsorbed, and the numerical exception that is adsorbed ground is high.
" many CD40 (relative molecular weight 4-5 ten thousand d) and CD40L (relative molecular weight 3.3 ten thousand d) express in the artery congee shape lump in the cerebral infarction blood samples of patients.
The CD40-CD40L system all plays an important role in each stage in atherosclerotic.In human artery's AP, all express CD40 and CD40L on endothelial cell, macrophage and the smooth muscle cell, and in normal arterial tissue, do not express.Cerebral atherosclerosis is the main pathogenic factor of acute cerebral ischemia, in the lesion growth process, the various kinds of cell factor such as interleukin 1 β (IL-1 β). interleukin-6 (IL-6), tumor necrosis factor (TNF-α) and interferon gamma (IFN-γ) can promote endothelial cell monocytes CD40L
1, can excite that CD40 and CD40L's is interconnected
1Thereby promoting E to select plain (CD62E), iuntercellular adhesion molecule-1 (ICAM-1) and blood vessel adhesion molecule-1 (VCAM-1) to express increases.And then mediation activated blood platelet or endothelial cell stick with neutrophil leucocyte and monocyte, further causes vascular dysfunctions and tissue damage.Because going down of inner skin cell function, neutrophil leucocyte sticks the enhancing of function, and ischemic tissue of brain discharges TXA2, LTB4, PAF, LTB46, chemotactic factor (CF)s such as COX-2 and complement
[8], cause capilary to block and vasomotor dysfunction.Matrix metalloproteinase (MMPS) mediation connective tissue degradation, removing and the reconstruction that produce after CD40 and CD40L interact simultaneously, destroy the collagen in the fibrous cap, cause plaque rupture, cause thrombus, arterial occlusion, participated in generation and the development of cerebral atherosclerosis." (annotating 1)
Resin of the present invention is interleukin-11 B, interleukin 6, TNF A and B2-microglobulin in the adsorption stripping blood at the embodiment of cerebral infarction illness.Separate above-mentioned toxicant through resin adsorption of the present invention, interrupted the evolution of cerebral infarction pathology, to such an extent as to delay to cure the cerebral infarction illness.
When curing the hypertension illness, adopt resin of the present invention also be influence blood pressure with adsorption stripping from blood big molecular toxicity material for example molecular weight be the parathormone high pressure factor of 9000d, to participate in malignant change all kinds of simultaneously, big molecular toxicity material comprises that toxic protein and other endotoxin adsorb in the lump, thereby interrupt the evolution of hypertension pathology, to such an extent as to delay to cure the hypertension illness.The inventor has obtained numerical example success case in clinical treatment.Patient Wang suffers from essential hypertension (family history is arranged), and blood pressure index 160/100 before the art is taken depressor throughout the year.Adopted resin of the present invention to carry out blood purification treatment on February 25th, 2009, postoperative blood pressure is recovered normal index and is remained on 120/80, postoperative 2 years so far, and the withdrawal blood pressure is bounce-back not.
Resin of the present invention is the excessive thyroxine factor and inflammatory factor in absorption and the eliminating blood samples of patients at hyperthyroid's treatment, cures the hyperthyroidism illness to such an extent as to alleviate.A routine clinical case that adopts the present invention to treat the hyperthyroid, patient Wang, 65 years old age, the male sex.Suffer from hypertension, (blood pressure is 100-120/180-200) and hyperthyroidism for many years.Take depressor every day, morning and afternoon each once, each ten multi-discs.The eyes evagination, facial congested.Successively through twice blood purification treatment of the present invention, between two weeks at interval.Through about one month self adjusting, adjustment period, do not take medicine after the two treatments.Postoperative surpasses 1 year at present, and hyperthyroid symptom disappears substantially.Hypertension is obviously alleviated.Substantially no longer take depressor now, blood is stabilized between 80/120 substantially.
Each single index restricted portion of resin of the present invention can have variation slightly, and this variation must follow the correspondence of other index to change; This corresponding relation comprises: an index descends and causes that another index rises, and perhaps an index rises and causes that another index rises simultaneously; But do not comprise that three indexs descend simultaneously; Excursion floating about 10-20% does not greatly influence its application, and these variations also should be included in protection scope of the present invention.There is certain inverse relation each other in every index of resin of the present invention, and for example enlarging pore volume can influence specific area decline.But the relation that also exists two indexs of correlation to rise simultaneously simultaneously, when for example specific area enlarged, pore volume also increased.The variation of every index of resin of the present invention is relevant with molecular weight and the molecular diameter of the material of want specific aim absorption.The adsorbent molecular weight is big, and what at first consider is the aperture of resin.
Resin of the present invention can also be applied in the treatment of other difficult illness, for example as medical adsorbent: hyperlipemia, tumour etc.; Every illness that relates to the virus initiation relevant with the blood conduction, the illness of perhaps accumulating the endotoxin material initiation in blood can adopt in clinical, and all certain curative effect can be arranged.
The present invention is in for example being applied to the treating AIDS process time, its generation to all toxicants that causes a disease, to comprising the absorption kill activity of virocyte, not only be expressed as the just separation of movable virus absorption in blood, also be expressed as the removing to related compound virus or toxicant, thereby cut off virus transcription process energy needed supply chains such as being hidden in intracellular HIV: and then cause hiding virus natural apoptosis when the life cycle termination of himself.
In addition, industry is particularly paid close attention in academic discussion: when being subjected to HIV to infect macrophage and T-CD4 death the HIV virokine takes place and spread explosively, so that cause the situation of large-scale infection, when adopting the present invention to treat, can not take place.HIV virokine blast process occurs in the blood, when it is blasted, adopts the technology of the present invention to be hidden in the chance that the infected huge HIV virokine of having a liking in cell and the T-CD4 cell is thoroughly removed from blood just.
The present invention has outstanding substantive distinguishing features and is that macroporous absorbent resin of the present invention has unprecedented aperture, pore volume and specific area; Substantially opened up macroporous absorbent resin at medical domain, particularly the application prospect of clinical medicine domain; And for adopting the blood purification mode to give treatment to the difficult illness that this prehuman feels simply helpless, for example AIDS, cerebral infarction and hypertension, tumour, hyperthyroidism etc. have been opened up bright future.
The present invention has obvious improvement and is, macroporous absorbent resin of the present invention is easy to use in clinical medicine, easy operating, and is easy to utilize, and its cost is also than present with low cost at other clinical technology of similar illness.
Application of the present invention is to technological progress and guarantee that human health has epoch making significance.
Annotate 1: this section literal draws doctor Xu Junfeng that instructs from the quick academician of the former president Shi Xue of No.1 Hospital Attached to Tianjin College of Traditional Chinese Medicine about the paper of " consciousness regaining acupuncture therapy treatment cerebral infarction ".
Claims (3)
1. medical macroporous absorbent resin is characterized in that: be resin balls with styrene-divinylbenzene material as the resin framework, its pore diameter range is in the 22-100 nanometer; Specific area is between 1000 square metres/g to 3000 square metre/g; Pore volume is between 6.000e-01cc/g to 9.000e-01cc/g; Resin surface coats protein film.
2. according to the described medical macroporous absorbent resin of claim 1, it is characterized in that coating protein film and have polarity.
3. application process of medical macroporous absorbent resin as claimed in claim 1 or 2, it is characterized in that the adsorbent as blood perfusion device, absorption is all kinds of in the blood in people's extracorporal circulatory system bloody path approaches and surpasses the big molecule poisonous substance of 10,000 d and excessive macromolecular components; Blood samples of patients is purified.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110195335 CN102847521B (en) | 2011-06-28 | 2011-07-05 | Macro-porous adsorption resin and its application |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110176346.3 | 2011-06-28 | ||
| CN201110176346 | 2011-06-28 | ||
| CN 201110195335 CN102847521B (en) | 2011-06-28 | 2011-07-05 | Macro-porous adsorption resin and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102847521A CN102847521A (en) | 2013-01-02 |
| CN102847521B true CN102847521B (en) | 2013-07-10 |
Family
ID=47394736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110195335 Active CN102847521B (en) | 2011-06-28 | 2011-07-05 | Macro-porous adsorption resin and its application |
| CN2011102264087A Pending CN102848679A (en) | 2011-06-28 | 2011-08-09 | Composite functional fabric |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102264087A Pending CN102848679A (en) | 2011-06-28 | 2011-08-09 | Composite functional fabric |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102847521B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357383A (en) * | 2012-03-31 | 2013-10-23 | 重庆赛英思医疗器械股份有限公司 | Macroporous adsorbent resin and application |
| CN103127562A (en) * | 2013-02-04 | 2013-06-05 | 于杰 | Integrated hemoperfusion apparatus |
| CN103483487B (en) * | 2013-08-01 | 2015-06-24 | 天津市阳权医疗器械有限公司 | Novel structure product, preparation method and use of styrenic resin |
| CN104689804B (en) * | 2013-08-12 | 2016-03-02 | 天津市阳权医疗器械有限公司 | For adsorbing the phenylethylene resin series of AIDS virus molecule in blood |
| CN104415739A (en) * | 2013-08-28 | 2015-03-18 | 天津市阳权医疗器械有限公司 | Application of styrene-divinylbenzene medical resin |
| CN104415015A (en) * | 2013-09-03 | 2015-03-18 | 于杰 | Poison-drawing-out dressing |
| CN103536977A (en) * | 2013-11-04 | 2014-01-29 | 于杰 | Hemoperfusion apparatus |
| CN103736161A (en) * | 2014-01-15 | 2014-04-23 | 倪吉喆 | Hepatitis delta virus specificity plasma adsorption column and using method for same |
| CN103691016A (en) * | 2014-01-15 | 2014-04-02 | 倪自谦 | Aids virus specific plasma adsorption column and application method thereof |
| CN103691017A (en) * | 2014-01-15 | 2014-04-02 | 倪自谦 | Hepatitis B virus specificity plasma adsorption column and using method thereof |
| CN103721307A (en) * | 2014-01-15 | 2014-04-16 | 倪自谦 | Hepatitis C virus specificity plasma adsorption column and using method thereof |
| CN104174385B (en) * | 2014-07-28 | 2016-07-06 | 南开大学 | A kind of adsorbent for bilirubin for blood perfusion |
| CN104096278A (en) * | 2014-08-07 | 2014-10-15 | 天津市阳权医疗器械有限公司 | Blood perfusion device special for adsorbing 'Ebola' filoviruses |
| CN104693332A (en) * | 2014-10-01 | 2015-06-10 | 于杰 | Glycosylated medical macroporous adsorption resin |
| CN104353143A (en) * | 2014-11-28 | 2015-02-18 | 于杰 | Adsorbent for treating drug dependence and usage thereof |
| CN105816420A (en) * | 2014-12-31 | 2016-08-03 | 于杰 | Resin adsorbent suppository |
| CN106268951A (en) * | 2015-05-15 | 2017-01-04 | 于杰 | transition metal activation, catalyst |
| CN106994336A (en) * | 2016-01-25 | 2017-08-01 | 于杰 | Suitable for the medical polymeric adsorbent of accurate blood purification therapy |
| CN105749886A (en) * | 2016-04-08 | 2016-07-13 | 华南理工大学 | Medical polymeric microsphere adsorbent for hemoperfusion apparatus and preparation method of medical polymeric microsphere adsorbent |
| CN106267410B (en) * | 2016-07-01 | 2019-03-08 | 翁炳焕 | HIV infection cell separator |
| EP3290067B1 (en) * | 2016-09-06 | 2021-03-03 | Gambro Lundia AB | Liver support system |
| CN108855003B (en) * | 2018-06-28 | 2021-01-05 | 南开大学 | Immunoadsorbent for removing inflammatory factors in blood and preparation method thereof |
| CN113274404A (en) * | 2020-06-28 | 2021-08-20 | 天翊生物医药科技(天津)有限公司 | New application of medical adsorption resin and helicobacter pylori eliminating medicine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612552A (en) * | 2008-06-26 | 2009-12-30 | 罗门哈斯公司 | Friedel-crafts reaction post-crosslinking adsorbent and preparation method thereof |
| CN102049242A (en) * | 2011-01-08 | 2011-05-11 | 广州康盛生物科技有限公司 | Anion resin for bilirubin absorption and preparation method thereof |
| CN102093499A (en) * | 2010-12-15 | 2011-06-15 | 安徽皖东化工有限公司 | Method for preparing adsorbent resin with ultra-high specific surface area |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2585468A1 (en) * | 2004-10-26 | 2006-05-04 | Reemay, Inc. | Composite fabric with controlled release of functional chemicals |
| US20120309851A1 (en) * | 2009-05-04 | 2012-12-06 | Nai-Hong Li | Process for Reducing Residual Surface Material from Porous Polymers |
| CN201692163U (en) * | 2010-04-16 | 2011-01-05 | 南京淼润森工贸有限公司 | Flat, stiff and smooth absorbent pad |
-
2011
- 2011-07-05 CN CN 201110195335 patent/CN102847521B/en active Active
- 2011-08-09 CN CN2011102264087A patent/CN102848679A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612552A (en) * | 2008-06-26 | 2009-12-30 | 罗门哈斯公司 | Friedel-crafts reaction post-crosslinking adsorbent and preparation method thereof |
| CN102093499A (en) * | 2010-12-15 | 2011-06-15 | 安徽皖东化工有限公司 | Method for preparing adsorbent resin with ultra-high specific surface area |
| CN102049242A (en) * | 2011-01-08 | 2011-05-11 | 广州康盛生物科技有限公司 | Anion resin for bilirubin absorption and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 含有悬挂双键的苯乙烯-二乙烯苯大孔共聚物的合成及吸附性能研究;金鑫 等;《离子交换与吸附》;19921231;第8卷(第6期);508-512 * |
| 金鑫 等.含有悬挂双键的苯乙烯-二乙烯苯大孔共聚物的合成及吸附性能研究.《离子交换与吸附》.1992,第8卷(第6期),508-512. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102847521A (en) | 2013-01-02 |
| CN102848679A (en) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847521B (en) | Macro-porous adsorption resin and its application | |
| CN102791277B (en) | The improvement of chronic prostatitis, interstitial cystitis and/or urination disorder or therapeutic agent | |
| CN105455296A (en) | Self-curing conditioning shoe having medical therapy function | |
| CN105748543B (en) | A Chinese medicinal composition for treating rheumatic diseases, and its preparation method | |
| CN105056376A (en) | Medical instrument for treating cervicitis and cervix HPV infection | |
| CN203354990U (en) | Double plasma molecular adsorption system | |
| CN102559823B (en) | Frog peel extract and extracting method thereof | |
| CN102258802B (en) | A kind of Novel multifunctional hemostatic dressing | |
| CN102370710B (en) | Medicament for treating otitis media and preparation method thereof | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| CN1160123C (en) | Use of ulinastatin in treating SARS and medicinal composition thereof | |
| CN103356848A (en) | Traditional Chinese medicine and preparation method thereof as well as Chinese herba preparation and preparation method of plaster | |
| AU2021200357B2 (en) | Use of mesenchymal stem cells in the treatment of viral infections and/or complications caused by viral infections | |
| CN101537019B (en) | Medicine for curing tympanitis | |
| CN107485655B (en) | Application of peach blossom extract in preparation of medicine for treating prostatitis | |
| CN108498521A (en) | Application of the cycloastragenol in preparing the drug for inhibiting abdominal aneurvsm | |
| CN102284094B (en) | Non-drug therapy system for septicopyemia caused by drug-resistance bacteria | |
| CN112043736A (en) | Purslane active component and preparation method and application thereof | |
| JP6966763B2 (en) | Improvement or treatment of chondromalacia patella | |
| CN109090310A (en) | A kind of medicinal herb tea of the immunity that tonifies the kidney to relieve mental strain, improves and its preparation process | |
| CN101224263A (en) | Chinese traditional medicine pill for treating psoriasis and various tinea, furuncle, shingles | |
| CN100548314C (en) | Snake venom cytotoxin and preparation method thereof and application | |
| CN102716510B (en) | Moisture-retention nano-silver burn and scald plaster | |
| RU2162352C1 (en) | Method for treating psoriasis | |
| WO2021237930A1 (en) | Application of mesenchymal stem cells in treatment of patients with viral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN YANGQUAN MEDICAL DEVICES CO., LTD. Free format text: FORMER OWNER: YU JIE Effective date: 20140714 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100012 CHAOYANG, BEIJING TO: 300222 JINNAN, TIANJIN |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140714 Address after: 300222 north side of outer ring road, East Mountain Road, Jinnan District, Tianjin Patentee after: Tianjin Yangquan Medical Devices Co., Ltd. Address before: 100012 Beijing city Chaoyang District Beiyuan Mo pigweed Park Building No. 7 room 2502 Patentee before: Yu Jie |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190807 Address after: 264210 No. 1 Weigao Road, Chucun Town, Weihai Torch High-tech Industrial Development Zone, Shandong Province Patentee after: Weihai Weigaoyangquan Biological Co., Ltd. Address before: 300222 north side of outer ring road, East Mountain Road, Jinnan District, Tianjin Patentee before: Tianjin Yangquan Medical Devices Co., Ltd. |
|
| TR01 | Transfer of patent right |